- Home
- CAVA vs RGEN Comparison
CAVA vs RGEN Comparison
Compare CAVA & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- RGEN
- Stock Information
- Founded
- CAVA 2006
- RGEN 1981
- Country
- CAVA United States
- RGEN United States
- Employees
- CAVA N/A
- RGEN N/A
- Industry
- CAVA Restaurants
- RGEN Medical/Dental Instruments
- Sector
- CAVA Consumer Discretionary
- RGEN Health Care
- Exchange
- CAVA Nasdaq
- RGEN Nasdaq
- Market Cap
- CAVA 9.4B
- RGEN 8.2B
- IPO Year
- CAVA 2023
- RGEN N/A
- Fundamental
- Price
- CAVA $125.41
- RGEN $141.78
- Analyst Decision
- CAVA Buy
- RGEN Buy
- Analyst Count
- CAVA 13
- RGEN 10
- Target Price
- CAVA $109.83
- RGEN $188.38
- AVG Volume (30 Days)
- CAVA 4.7M
- RGEN 926.2K
- Earning Date
- CAVA 11-05-2024
- RGEN 10-29-2024
- Dividend Yield
- CAVA N/A
- RGEN N/A
- EPS Growth
- CAVA N/A
- RGEN N/A
- EPS
- CAVA 0.38
- RGEN N/A
- Revenue
- CAVA $845,224,000.00
- RGEN $602,354,000.00
- Revenue This Year
- CAVA $30.85
- RGEN $0.08
- Revenue Next Year
- CAVA $20.92
- RGEN $12.97
- P/E Ratio
- CAVA $333.97
- RGEN N/A
- Revenue Growth
- CAVA 31.01
- RGEN N/A
- 52 Week Low
- CAVA $29.05
- RGEN $110.45
- 52 Week High
- CAVA $128.18
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- CAVA 71.73
- RGEN 43.50
- Support Level
- CAVA $113.13
- RGEN $138.80
- Resistance Level
- CAVA $122.27
- RGEN $150.72
- Average True Range (ATR)
- CAVA 4.49
- RGEN 4.98
- MACD
- CAVA 0.40
- RGEN -0.92
- Stochastic Oscillator
- CAVA 90.24
- RGEN 24.50
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
About RGEN Repligen Corporation
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.